Zeit | Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
10.03. | Galderma @ AAD 2024: New Data Demonstrate the Long-Term Efficacy of Nemolizumab in Prurigo Nodularis and Its Durability in Atopic Dermatitis | 376 | Business Wire | Nemolizumab is a first-in-class investigational monoclonal antibody designed to provide relief from itch by targeting IL-31
One-year data from an interim analysis of the OLYMPIA long-term... ► Artikel lesen | |
10.03. | Incyte Presents New Late-Breaking Data from Phase 2 Study Evaluating Povorcitinib in Patients with Prurigo Nodularis | 505 | Business Wire | Randomized Phase 2 study met its primary and secondary endpoints following 16 weeks of treatment across all dosing groups, reinforcing povorcitinib's potential role in treating prurigo nodularis... ► Artikel lesen |
Suchbegriffe der letzen 24 h | Anzahl |
---|---|
GAMESTOP | 4.647 |
EVOTEC | 4.167 |
TUI | 3.212 |
NEL | 2.490 |
BAYER | 1.946 |
NVIDIA | 1.855 |
PLUG POWER | 1.848 |
AMC ENTERTAINMENT | 1.846 |
SIEMENS ENERGY | 1.786 |
RHEINMETALL | 1.719 |
DEUTSCHE BANK | 1.528 |
SIEMENS | 1.289 |
RENK GROUP | 1.263 |
COMMERZBANK | 1.230 |
AIXTRON SE | 1.178 |
HEIDELBERGER DRUCK | 1.144 |
ALIBABA | 1.140 |
MERCEDES-BENZ | 1.044 |
VOLKSWAGEN | 1.021 |
BYD | 1.020 |
DEUTSCHE TELEKOM | 996 |
RWE | 967 |
SUPER MICRO COMPUTER | 956 |
ALLIANZ | 940 |
E.ON | 864 |